Shareholders controlling at least 5% of the votes at the GeneralShareholders Meeting of Ryvu Therapeutics S.A. convened on June 26th,2025

The Management Board of Ryvu Therapeutics S.A. with its registeredoffice in Krakow, Poland ("Company", "Ryvu") hereby announces that thefollowing shareholders controlled at least 5% of the vote at the GeneralShareholders Meeting of the Company ("General Meeting") convened on June26th, 2025:

1. Paweł Przewięźlikowski: 3,982,160 shares of the Company, whichentitled to exercise 7,482,160 votes, which constituted respectively34.45 % of shares at the GM and 49.69% of votes at the GM and 27.54% inthe total number of votes.

2. Nationale-Nederlanden Otwarty Fundusz Emerytalny: 1,385,000 shares inthe Company, which entitled to exercise 1,385,000 votes, whichconstituted 11.98% of shares at the GM and 9.20% of votes at the GM and5.11% of the total number of votes.

3. Allianz Polska Otwarty Fundusz Emerytalny: 2,132,540 shares of theCompany, which entitled to exercise 2,132,540 votes, which constitutedrespectively 18.45% of shares at the GM and 14.16% of votes at the GMand 7.85% in the total number of votes.

4. BioNTech SE: 1.917.437 shares of the Company, which entitled toexercise 1,917,437 votes, which constituted respectively 16.59% ofshares at the GM and 12.73% of votes at the GM and 7.06% in the totalnumber of votes.

According to the attendance list, shareholders holding 11,557,727 sharesentitling them to exercise 15,057,727 votes were represented at the GM.

The total number of shares in the Company is 23,120,148, entitling to27,170,148 votes.

Disclaimer: This English language translation has been prepared solelyfor the convenience of English speaking readers. Despite all the effortsdevoted to this translation, certain discrepancies, omissions orapproximations may exist. In case of any differences between the Polishand the English versions, the Polish version shall prevail. RyvuTherapeutics S.A., its representatives and employees decline allresponsibility in this regard.